Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 4
1974 11
1975 8
1976 8
1977 4
1978 8
1979 8
1980 8
1981 16
1982 14
1983 41
1984 27
1985 35
1986 31
1987 26
1988 20
1989 17
1990 23
1991 22
1992 15
1993 22
1994 19
1995 16
1996 20
1997 24
1998 18
1999 22
2000 11
2001 20
2002 16
2003 6
2004 7
2005 9
2006 16
2007 27
2008 14
2009 15
2010 16
2011 17
2012 21
2013 23
2014 18
2015 11
2016 13
2017 11
2018 7
2019 8
2020 16
2021 6
2022 3
2023 5

Text availability

Article attribute

Article type

Publication date

Search Results

754 results

Results by year

Filters applied: . Clear all
Page 1
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, Saavedra MT, Saiman L, Taylor-Cousar JL, Nick JA. Nichols DP, et al. J Cyst Fibros. 2017 May;16(3):358-366. doi: 10.1016/j.jcf.2016.12.003. Epub 2016 Dec 24. J Cyst Fibros. 2017. PMID: 28025037 Free PMC article. Clinical Trial.
BACKGROUND: Concomitant use of oral azithromycin and inhaled tobramycin occurs in approximately half of US cystic fibrosis (CF) patients. ...CFQ-R respiratory symptom score decreased 1.8 points during inhaled tobramycin and increased 8.3 points during subsequent inh …
BACKGROUND: Concomitant use of oral azithromycin and inhaled tobramycin occurs in approximately half of US cystic fibrosis (CF) patie …
A clinical trial of teicoplanin compared with a combination of flucloxacillin and tobramycin as antibiotic prophylaxis for cardiac surgery: the use of a scoring method to assess the incidence of wound infection.
Wilson AP, Grüneberg RN, Treasure T, Sturridge MF. Wilson AP, et al. J Hosp Infect. 1986 Mar;7 Suppl A:105-12. doi: 10.1016/0195-6701(86)90015-0. J Hosp Infect. 1986. PMID: 2871092 Clinical Trial.
A prospective randomized clinical trial is in progress to compare the efficacy of teicoplanin with flucloxacillin and tobramycin in the prevention of endocarditis and wound infection following cardiac surgery. To date, 198 patients have completed the trial, of whom 95 have …
A prospective randomized clinical trial is in progress to compare the efficacy of teicoplanin with flucloxacillin and tobramycin in t …
Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients.
Schentag JJ, Plaut ME, Cerra FB. Schentag JJ, et al. Antimicrob Agents Chemother. 1981 May;19(5):859-66. doi: 10.1128/AAC.19.5.859. Antimicrob Agents Chemother. 1981. PMID: 7294770 Free PMC article. Clinical Trial.
A total of 201 critically ill patients were studied during 267 courses of gentamicin or tobramycin treatment (139 gentamicin courses and 128 tobramycin courses). ...Previous aminoglycoside treatment (usually gentamicin) had occurred more frequently in the tobramy …
A total of 201 critically ill patients were studied during 267 courses of gentamicin or tobramycin treatment (139 gentamicin courses …
A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.
Chen M, Gong L, Sun X, Gu Y, He X, Qu J, Wang L, Zhang M, Zhong X. Chen M, et al. Curr Med Res Opin. 2012 Mar;28(3):385-94. doi: 10.1185/03007995.2012.659723. Epub 2012 Feb 7. Curr Med Res Opin. 2012. PMID: 22256909 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) and dexamethasone 0.1%/tobramycin 0.3% (DM/T) ophthalmic suspensions in a Chinese population with ocular inflammation associated with blepharokeratoconjunctivitis (BKC …
OBJECTIVE: To compare the efficacy and safety of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) and dexamethasone 0.1%/tobramyc …
Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin.
Cox ZL, Nelsen CL, Waitman LR, McCoy JA, Peterson JF. Cox ZL, et al. Am J Health Syst Pharm. 2011 Apr 1;68(7):624-32. doi: 10.2146/ajhp100155. Am J Health Syst Pharm. 2011. PMID: 21411805 Free PMC article. Clinical Trial.
PURPOSE: The impact of clinical decision support (CDS) on initial doses and intervals and pharmacokinetic outcomes of amikacin and tobramycin therapy was evaluated. METHODS: A complex CDS advisor to provide guidance on initial dosing and monitoring of aminoglycoside orders …
PURPOSE: The impact of clinical decision support (CDS) on initial doses and intervals and pharmacokinetic outcomes of amikacin and tobram …
Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL, Cockrum P, Meier E, Hammonds WM, Silverstein B, Silverstein S. Torkildsen GL, et al. Curr Med Res Opin. 2011 Jan;27(1):171-8. doi: 10.1185/03007995.2010.539603. Epub 2010 Dec 7. Curr Med Res Opin. 2011. PMID: 21138337 Clinical Trial.
OBJECTIVE: To evaluate the clinical efficacy and safety of tobramycin/dexamethasone (TobraDex ST ; 'ST') ophthalmic suspension 0.3%/0.05% compared to azithromycin (Azasite) ophthalmic solution (1%) in the treatment of moderate to severe blepharitis/blepharoconjunctivitis. …
OBJECTIVE: To evaluate the clinical efficacy and safety of tobramycin/dexamethasone (TobraDex ST ; 'ST') ophthalmic suspension 0.3%/0 …
Moxalactam vs tobramycin-clindamycin. A randomized trial in secondary peritonitis.
Stellato TA, Danziger LH, Hau T, Gauderer MW, Ferron JL, Gordon N. Stellato TA, et al. Arch Surg. 1988 Jun;123(6):714-7. doi: 10.1001/archsurg.1988.01400300060009. Arch Surg. 1988. PMID: 3285809 Review.
Other complications included hypoprothrombinemia (tobramycin-clindamycin, five; moxalactam, five), renal dysfunction (tobramycin-clindamycin, three; moxalactam, one), and superinfection (tobramycin-clindamycin, nine; moxalactam, six). More wound infections we …
Other complications included hypoprothrombinemia (tobramycin-clindamycin, five; moxalactam, five), renal dysfunction (tobramycin …
A prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled Tobramycin in patients with ventilator-associated pneumonia (iToVAP).
Angermair S, Deja M, Thronicke A, Grehn C, Akbari N, Uhrig A, Asgarpur G, Spies C, Treskatsch S, Schwarz C. Angermair S, et al. Anaesth Crit Care Pain Med. 2023 Oct;42(5):101249. doi: 10.1016/j.accpm.2023.101249. Epub 2023 May 20. Anaesth Crit Care Pain Med. 2023. PMID: 37217019 Free article. Clinical Trial.
Therefore, we aimed to investigate the efficacy of the adjunctive inhaled Tobramycin in patients with pneumonia caused by Gram-negative pathogens in addition to the standard systemic treatment. ...The increased eradication frequency was not associated with increased patien …
Therefore, we aimed to investigate the efficacy of the adjunctive inhaled Tobramycin in patients with pneumonia caused by Gram-negati …
Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin.
Lerner AM, Reyes MP, Cone LA, Blair DC, Jansen W, Wright GE, Lorber RR. Lerner AM, et al. Lancet. 1983 May 21;1(8334):1123-6. doi: 10.1016/s0140-6736(83)92864-7. Lancet. 1983. PMID: 6133153 Clinical Trial.
The mean daily dose of netilmicin (237 mg) was higher than that of tobramycin (211 mg), p less than 0.01, but the mean duration of therapy was longer with tobramycin (9.4 days versus 8.7 days), p less than 0.01. The netilmicin cohort also had more serious underlying …
The mean daily dose of netilmicin (237 mg) was higher than that of tobramycin (211 mg), p less than 0.01, but the mean duration of th …
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; EPIC Study Group. Treggiari MM, et al. Contemp Clin Trials. 2009 May;30(3):256-68. doi: 10.1016/j.cct.2009.01.003. Epub 2009 Jan 15. Contemp Clin Trials. 2009. PMID: 19470318 Free PMC article. Clinical Trial.
Using a factorial design, trial participants are assigned for 18 months to either anti-pseudomonal treatment on a scheduled quarterly basis (cycled therapy) or based on recovery of Pa from quarterly respiratory cultures (culture-based therapy). The study drugs include inhaled …
Using a factorial design, trial participants are assigned for 18 months to either anti-pseudomonal treatment on a scheduled quarterly basis …
754 results